Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

NCT02296242 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: BVD-523

Sponsor

BioMed Valley Discoveries, Inc